BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6. [PMID: 10406263 DOI: 10.1111/j.1572-0241.1999.01234.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 101] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198:333-339. [PMID: 19375064 DOI: 10.1016/j.amjsurg.2008.12.031] [Cited by in Crossref: 120] [Cited by in F6Publishing: 100] [Article Influence: 10.0] [Reference Citation Analysis]
2 Smith RA, Bosonnet L, Ghaneh P, Sutton R, Evans J, Healey P, Garvey C, Hughes M, Raraty M, Campbell F, Neoptolemos JP. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 2008;143:658-66. [PMID: 18436014 DOI: 10.1016/j.surg.2007.12.014] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
3 Venkatesh PG, Navaneethan U, Shen B, McCullough AJ. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci. 2013;58:850-857. [PMID: 23007734 DOI: 10.1007/s10620-012-2401-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
4 Kim B, Lee K, Moon T, Kang P, Lee J, Kim J, Rhee J. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Digestive and Liver Disease 2009;41:364-9. [DOI: 10.1016/j.dld.2008.12.094] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
5 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
6 Wen H, Yoo SS, Kang J, Kim HG, Park JS, Jeong S, Lee JI, Kwon HN, Kang S, Lee DH, Park S. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol 2010;52:228-33. [PMID: 20036026 DOI: 10.1016/j.jhep.2009.11.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
7 Zeng P, Li H, Chen Y, Pei H, Zhang L. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases. Prog Mol Biol Transl Sci. 2019;162:253-264. [PMID: 30905455 DOI: 10.1016/bs.pmbts.2018.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Jung JH, Lee HJ, Lee HS, Jo JH, Cho IR, Chung MJ, Park JY, Park SW, Song SY, Bang S. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma. World J Gastroenterol 2017;23:3301-8. [PMID: 28566890 DOI: 10.3748/wjg.v23.i18.3301] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
9 Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, Berry DP, Dennison AR. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 2008;53:3213-3217. [PMID: 18465243 DOI: 10.1007/s10620-008-0289-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
10 Passerini R, Riggio D, Salvatici M, Zorzino L, Radice D, Sandri MT. Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update. Clinical Chemical Laboratory Medicine 2007;45. [DOI: 10.1515/cclm.2007.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
11 Tang Y, Cui Y, Zhang S, Zhang L. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. Prog Mol Biol Transl Sci 2019;162:121-40. [PMID: 30905445 DOI: 10.1016/bs.pmbts.2019.01.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Wang X, Fu XH, Qian ZL, Zhao T, Duan AQ, Ruan X, Zhu B, Yin L, Zhang YJ, Yu WL. Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study. Transl Oncol 2021;14:100908. [PMID: 33059123 DOI: 10.1016/j.tranon.2020.100908] [Reference Citation Analysis]
13 De Rosa A, Cameron IC, Gomez D. Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford). 2016;18:13-20. [PMID: 26776846 DOI: 10.1016/j.hpb.2015.10.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
14 Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270. [PMID: 17097848 DOI: 10.1016/j.ejso.2006.10.004] [Cited by in Crossref: 467] [Cited by in F6Publishing: 414] [Article Influence: 31.1] [Reference Citation Analysis]
15 Tsai MJ, Liao KS, Shih PM, Lee KT, Chuang WL, Chiu YJ, Lin ZY. Relapsed acute pancreatitis as the initial presentation of pancreatic cancer in a young man: a case report. Kaohsiung J Med Sci 2010;26:448-55. [PMID: 20705257 DOI: 10.1016/S1607-551X(10)70072-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Robertson AG, Davidson BR. Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9. Eur J Gastroenterol Hepatol. 2007;19:167-169. [PMID: 17273004 DOI: 10.1097/meg.0b013e3280122879] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
17 De Marchi G, Paiella S, Luchini C, Capelli P, Bassi C, Frulloni L. Very high serum levels of CA 19-9 in autoimmune pancreatitis: Report of four cases and brief review of literature. J Dig Dis 2016;17:697-702. [PMID: 27579898 DOI: 10.1111/1751-2980.12403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Kim MS, Jeon TJ, Park JY, Choi J, Shin WC, Park SE, Seo JY, Kim YM. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease. Korean J Gastroenterol. 2017;70:96-102. [PMID: 28830135 DOI: 10.4166/kjg.2017.70.2.96] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 208] [Reference Citation Analysis]
20 Polat E, Duman U, Duman M, Atici AE, Reyhan E, Dalgic T, Bostanci EB, Yol S. Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer. Curr Oncol 2014;21:e1-7. [PMID: 24523606 DOI: 10.3747/co.21.1711] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
21 Thornthwaite JT, Mcduffee EC, Harris RB, Secor Mcvoy JR, Lane I. The cancer recognition (CARE) antibody test. Cancer Letters 2004;216:227-41. [DOI: 10.1016/s0304-3835(03)00161-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 97] [Article Influence: 12.2] [Reference Citation Analysis]
23 Mavros MN, Moris D, Karanicolas PJ, Katz MHG, O'Reilly EM, Pawlik TM. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. JAMA Surg 2021;156:663-72. [PMID: 33787841 DOI: 10.1001/jamasurg.2021.0149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Wadsworth CA, Lim A, Taylor-robinson SD, Khan SA. The risk factors and diagnosis of cholangiocarcinoma. Hepatol Int 2013;7:377-93. [DOI: 10.1007/s12072-012-9407-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
25 Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340-351. [PMID: 23331006 DOI: 10.2174/1566524011313030003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 91] [Article Influence: 2.4] [Reference Citation Analysis]
26 Shin EJ, Canto MI. The Clinical Assessment of Pancreatic Cancer. In: Beger HG, Matsuno S, Cameron JL, Rau BM, Sunamura M, Schulick RD, editors. Diseases of the Pancreas. Berlin: Springer Berlin Heidelberg; 2008. pp. 527-40. [DOI: 10.1007/978-3-540-28656-1_53] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Pappas S, Federle MP, Lokshin AE, Zeh HJ 3rd. Early detection and staging of adenocarcinoma of the pancreas. Gastroenterol Clin North Am 2007;36:413-29, x. [PMID: 17533087 DOI: 10.1016/j.gtc.2007.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
28 Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368-402. [PMID: 24183261 DOI: 10.1016/j.disamonth.2013.08.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 9.5] [Reference Citation Analysis]
29 Bowlus CL, Olson KA, Gershwin ME. Evaluation of indeterminate biliary strictures. Nat Rev Gastroenterol Hepatol. 2016;13:28-37. [PMID: 26526122 DOI: 10.1038/nrgastro.2015.182] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
30 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Reference Citation Analysis]
31 Lee HS, Jang CY, Kim SA, Park SB, Jung DE, Kim BO, Kim HY, Chung MJ, Park JY, Bang S, Park SW, Song SY. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Sci Rep 2018;8:3383. [PMID: 29467409 DOI: 10.1038/s41598-018-21823-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
32 Wang QH, Ji ZG, Chen ZG, Li HZ, Fan H, Fan XR, Shi BB, Fang Y. Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer. Int J Surg. 2015;15:113-116. [PMID: 25647541 DOI: 10.1016/j.ijsu.2015.01.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Davidson BR, Gurusamy K. Is preoperative histological diagnosis necessary for cholangiocarcinoma? HPB (Oxford) 2008;10:94-7. [PMID: 18773063 DOI: 10.1080/13651820801992633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
34 Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148-1154. [PMID: 18760544 DOI: 10.1016/j.ijrobp.2008.06.1483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
35 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
36 Jin X, Wu Y. Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels. Afr Health Sci 2015;15:123-30. [PMID: 25834540 DOI: 10.4314/ahs.v15i1.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
38 Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33:799-807. [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
39 Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MG. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 2008;95:453-9. [PMID: 18161888 DOI: 10.1002/bjs.6043] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
40 Kim SY, Lee HS, Bang SM, Han DH, Hwang HK, Choi GH, Chung MJ, Kim SU. Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:1828. [PMID: 33921232 DOI: 10.3390/cancers13081828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M. Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines. Ann Surg Oncol 2011;18:371-9. [DOI: 10.1245/s10434-010-1311-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
42 Skipworth JR, Timms JF, Pereira SP. Novel diagnostic and prognostic biomarkers in biliary tract cancer. Expert Opin Med Diagn 2013;7:487-99. [PMID: 23971898 DOI: 10.1517/17530059.2013.826646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
43 Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015;20:1019-1027. [PMID: 26245674 DOI: 10.1634/theoncologist.2015-0210] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
44 Lin Y, Wong SI, Wang Y, Lam C, Peng X. Periampullary Metastases from Breast Cancer: A Case Report and Literature Review. Case Rep Oncol Med 2019;2019:3479568. [PMID: 30729053 DOI: 10.1155/2019/3479568] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Shi J, Lew M, Zalupski MM, Roh MH, Kwon RS, Pang JC. Implication of Suspicious Cytology in Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Pancreatic Cancer. J Gastrointest Canc 2015;46:54-9. [DOI: 10.1007/s12029-014-9681-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Singh A, Gelrud A, Agarwal B. Biliary strictures: diagnostic considerations and approach. Gastroenterol Rep (Oxf). 2015;3:22-31. [PMID: 25355800 DOI: 10.1093/gastro/gou072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 49] [Article Influence: 10.4] [Reference Citation Analysis]
47 Madonia S, Aragona E, Maisano S, Montalbano L, Olivo M, Rossi F, Restivo G, Cottone M. CA 19-9 to Rule Out Pancreatic or Biliary Cancer Among Patients with Cholestasis: An Unsuitable Test? Dig Dis Sci 2007;52:1125-7. [DOI: 10.1007/s10620-006-9532-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
48 Blechacz BR, Gores GJ. Cholangiocarcinoma. Clinics in Liver Disease 2008;12:131-50. [DOI: 10.1016/j.cld.2007.11.003] [Cited by in Crossref: 156] [Cited by in F6Publishing: 137] [Article Influence: 12.0] [Reference Citation Analysis]
49 Lieto E, Castellano P, Ferraraccio F, Orditura M, De Vita F, Romano C, Pignatelli C, Galizia G. Normal interleukin-10 serum level opposed to high serum levels of carbohydrate antigen 19-9 and cancer antigens 125 and 50 in a case of true splenic cyst. Arch Med Res 2003;34:145-8. [PMID: 12700012 DOI: 10.1016/S0188-4409(02)00468-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
50 Kim HJ, Kim MH, Bae JS, Lee SS, Seo DW, Lee SK. Idiopathic acute pancreatitis. J Clin Gastroenterol. 2003;37:238-250. [PMID: 12960724 DOI: 10.1097/00004836-200309000-00010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
51 Chang MC, Chang YT, Su TC, Yang WS, Chen CL, Tien YW, Liang PC, Wei SC, Wong JM. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas 2007;35:16-21. [PMID: 17575540 DOI: 10.1097/MPA.0b013e3180547709] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
52 Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, Khor CJ, Ponnudurai R, Moon JH, Seo DW, Pantongrag-Brown L, Sangchan A, Pisespongsa P, Akaraviputh T, Reddy ND, Maydeo A, Itoi T, Pausawasdi N, Punamiya S, Attasaranya S, Devereaux B, Ramchandani M, Goh KL; Asia-Pacific Working Group on Hepatobiliary Cancers. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol. 2013;28:593-607. [PMID: 23350673 DOI: 10.1111/jgh.12128] [Cited by in Crossref: 135] [Cited by in F6Publishing: 101] [Article Influence: 16.9] [Reference Citation Analysis]
53 Chiang KC, Yeh CN, Lee WC, Jan YY, Hwang TL. Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection. World J Gastroenterol 2009;15:4305-10. [PMID: 19750574 DOI: 10.3748/wjg.15.4305] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
54 Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, Neoptolemos JP. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226-232. [PMID: 18577869 DOI: 10.1159/000140961] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
55 Zeni LB, Russi RF, Fialho AF, Fonseca AL, Sombrio LS, Rocha IC. Morbidity and mortality of pancreatic tumors undergoing surgical treatment. Arq Bras Cir Dig 2014;27:275-9. [PMID: 25626938 DOI: 10.1590/S0102-67202014000400011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
56 Kanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z. Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010;55:916-922. [PMID: 20189277 DOI: 10.1053/j.ajkd.2009.12.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
57 Park J, Kim MH, Kim KP, Park DH, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver. 2009;3:298-305. [PMID: 20431764 DOI: 10.5009/gnl.2009.3.4.298] [Cited by in Crossref: 104] [Cited by in F6Publishing: 81] [Article Influence: 8.7] [Reference Citation Analysis]
58 Copur MS, Obermiller A. Brief Commentary: Largest Randomized Trial of Biliary Tract Cancer Treatment With Cisplatin Plus Gemcitabine Versus Gemcitabine Alone: An Excellent Opportunity to Evaluate the Prognostic Value of Tumor Marker CA 19-9. Clinical Colorectal Cancer 2011;10:70-1. [DOI: 10.3816/ccc.2011.n.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Samarasena JB, Hu K. Hepatobiliary Manifestations of Gastrointestinal and Nutritional Disorders. Clinics in Liver Disease 2011;15:89-110. [DOI: 10.1016/j.cld.2010.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
60 Akdoğran M, Şaşmaz N, Kayhan B, Bıyıkoğrlu I, Dişibeyaz S, Şahin B. Extraordinarily Elevated Ca19-9 in Benign Conditions: A Case Report and Review of the Literature. Tumori 2001;87:337-9. [DOI: 10.1177/030089160108700513] [Cited by in Crossref: 46] [Cited by in F6Publishing: 22] [Article Influence: 15.3] [Reference Citation Analysis]
61 Nasief H, Hall W, Zheng C, Tsai S, Wang L, Erickson B, Li XA. Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9. Front Oncol. 2019;9:1464. [PMID: 31970088 DOI: 10.3389/fonc.2019.01464] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
62 Tesfaye AA, Azmi AS, Philip PA. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. Am J Pathol 2019;189:58-70. [PMID: 30558723 DOI: 10.1016/j.ajpath.2018.10.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
63 Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, Srivastava S, Frazier ML, Sen S, Hollingsworth MA, Rinaudo JA, Killary AM, Brand RE. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS One 2015;10:e0139049. [PMID: 26431551 DOI: 10.1371/journal.pone.0139049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
64 Yang J, Li S, Li J, Wang F, Chen K, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, Zhang H, Guo C. A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer. Pancreatology 2016;16:605-14. [DOI: 10.1016/j.pan.2016.04.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
65 Sivaraman A, Muthukrishnan A, Boopathy Senguttvan N, Anil Suchak S, Kannan U. Predictors of malignancy in pancreatic head mass: a prospective study. Pan Afr Med J 2011;9:30. [PMID: 22145063 DOI: 10.4314/pamj.v9i1.71206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
66 Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018;18:862-867. [PMID: 30249386 DOI: 10.1016/j.pan.2018.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
67 Jung KW, Kim MH, Lee TY, Kwon S, Oh HC, Lee SS, Seo DW, Lee SK. Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer. J Korean Med Sci 2007;22 Suppl:S79-85. [PMID: 17923760 DOI: 10.3346/jkms.2007.22.S.S79] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
68 Mu DQ, Wang GF, Peng SY. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis. World J Gastroenterol 2003;9:1815-8. [PMID: 12918127 DOI: 10.3748/wjg.v9.i8.1815] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
69 Gu X, Wang C, Deng H, Qing C, Liu R, Liu S, Xue X. Exosomal piRNA profiling revealed unique circulating piRNA signatures of cholangiocarcinoma and gallbladder carcinoma. Acta Biochim Biophys Sin (Shanghai). 2020;52:475-484. [PMID: 32369104 DOI: 10.1093/abbs/gmaa028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
70 Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol 2016;7:E45-51. [PMID: 27284488 DOI: 10.21037/jgo.2016.01.05] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
71 Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci. 2007;52:3140-3142. [PMID: 17404889 DOI: 10.1007/s10620-006-9164-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
72 Xu M, Sethi A. Diagnosing Biliary Malignancy. Gastrointestinal Endoscopy Clinics of North America 2015;25:677-90. [DOI: 10.1016/j.giec.2015.06.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
73 Ventrucci M, Pozzato P, Cipolla A, Uomo G. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 2009;41:357-63. [PMID: 18602352 DOI: 10.1016/j.dld.2008.04.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
74 van der Veek PP, de Vos Tot Nederveen Cappel WH, Langers AM, van Hoek B. Two patients with extremely elevated tumor markers: where is the malignancy? Gastroenterol Res Pract 2011;2011:123743. [PMID: 21760772 DOI: 10.1155/2011/123743] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
75 Ma WJ, Wu ZR, Shrestha A, Yang Q, Hu HJ, Wang JK, Liu F, Zhou RX, Li QS, Li FY. Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma. Hepatobiliary Surg Nutr 2018;7:251-69. [PMID: 30221153 DOI: 10.21037/hbsn.2018.03.14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
76 Seeree P, Pearngam P, Kumkate S, Janvilisri T. An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics. 2015;2015:179528. [PMID: 26421274 DOI: 10.1155/2015/179528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
77 Lenggenhager D, Bengs S, Fritsch R, Hussung S, Busenhart P, Endhardt K, Töpfer A, The FO, Bütikofer S, Gubler C, Scharl M, Morell B. β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. Clin Transl Gastroenterol 2021;12:e00395. [PMID: 34388137 DOI: 10.14309/ctg.0000000000000395] [Reference Citation Analysis]
78 Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level.Korean J Fam Med. 2019;40:314-322. [PMID: 30959581 DOI: 10.4082/kjfm.18.0057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
79 Lee JK, Enns R. Review of idiopathic pancreatitis. World J Gastroenterol. 2007;13:6296-6313. [PMID: 18081217 DOI: 10.3748/wjg.v13.i47.6296] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
80 Jin XL, Xu B, Wu YL. Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology. World J Gastroenterol 2014;20:14958-64. [PMID: 25356057 DOI: 10.3748/wjg.v20.i40.14958] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Patel KJ, Latif SU, de Calaca WM. An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report. J Hematol Oncol 2009;2:12. [PMID: 19284608 DOI: 10.1186/1756-8722-2-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
82 de la Cruz J, Hidalgo LA, Feliu J, Admella C, Muns R, del Bas M, Suñol X. [Gallbladder adenocarcinoma: tumoral staging, histological prognostic factors and survival]. Cir Esp 2005;77:18-21. [PMID: 16420877 DOI: 10.1016/s0009-739x(05)70797-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer--a review.Biomarkers. 2014;19:437-443. [PMID: 24857368 DOI: 10.3109/1354750X.2014.923048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 3.9] [Reference Citation Analysis]
84 Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas. 2007;34:318-324. [PMID: 17414054 DOI: 10.1097/mpa.0b013e31802ee9c7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
85 Suzuki K, Muraishi O, Tokue A. THE CORRELATION OF SERUM CARBOHYDRATE ANTIGEN 19-9 WITH BENIGN HYDRONEPHROSIS. Journal of Urology 2002;167:16-20. [DOI: 10.1016/s0022-5347(05)65372-4] [Cited by in Crossref: 27] [Article Influence: 1.4] [Reference Citation Analysis]
86 Lennon AM, Goggins M. Diagnostic and Therapeutic Response Markers. Pancreatic Cancer. New York: Springer; 2010. pp. 675-701. [DOI: 10.1007/978-0-387-77498-5_28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
87 Akimoto S, Banshodani M, Nishihara M, Nambu J, Kawaguchi Y, Shimamoto F, Dohi K, Sugino K, Ohdan H. Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9. Case Rep Gastroenterol. 2016;10:410-416. [PMID: 27721726 DOI: 10.1159/000448068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
88 Connor S, Bosonnet L, Alexakis N, Raraty M, Ghaneh P, Sutton R, Neoptolemos J. Serum CA19-9 Measurement Increases the Effectiveness of Staging Laparoscopy in Patients with Suspected Pancreatic Malignancy. Dig Surg 2005;22:80-5. [DOI: 10.1159/000085297] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
89 Fernandez Y Viesca M, Arvanitakis M. Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines. Clin Exp Gastroenterol. 2019;12:415-432. [PMID: 31807048 DOI: 10.2147/ceg.s195714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
90 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Gilliam A, Lobo D, Rowlands B, Beckingham I. The ‘two-week’ target for the diagnosis of pancreatic carcinoma: an achievable aim? European Journal of Surgical Oncology (EJSO) 2003;29:575-9. [DOI: 10.1016/s0748-7983(03)00112-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Urgell E, Puig P, Boadas J, Capellà G, Queraltó JM, Boluda R, Antonijuan A, Farré A, Lluís F, González-Sastre F. Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer. Eur J Cancer. 2000;36:2069-2075. [PMID: 11044643 DOI: 10.1016/s0959-8049(00)00288-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
93 Akgül T, Nuhoğlu B, Ayyildiz A, Balci U, Ayyildiz SN, Germiyanoğlu C. Do hydronephrosis and extracorporeal shock wave lithotripsy affect carbohydrate antigens? Int Urol Nephrol 2007;39:1001-4. [PMID: 17334832 DOI: 10.1007/s11255-006-9169-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Singh A, Siddiqui UD. The Role of Endoscopy in the Diagnosis and Management of Cholangiocarcinoma. J Clin Gastroenterol 2015;49:725-37. [PMID: 26340677 DOI: 10.1097/MCG.0000000000000390] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
95 Oguro S, Esaki M, Kishi Y, Nara S, Shimada K, Ojima H, Kosuge T. Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma. Ann Surg Oncol 2015;22:1915-24. [PMID: 25404474 DOI: 10.1245/s10434-014-4232-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
96 Marcouizos G, Ignatiadou E, Papanikolaou GE, Ziogas D, Fatouros M. Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases J 2009;2:6662. [PMID: 19829841 DOI: 10.4076/1757-1626-2-6662] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
97 Rupesh P, Manoj P, Vijay Kumar S. Biomarkers in carcinoma of the gallbladder. Expert Opinion on Medical Diagnostics 2008;2:511-26. [DOI: 10.1517/17530059.2.5.511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
98 Beyazit Y, Sayilir A, Koklu S, Torun S, Suvak B, Tas A, Purnak T, Kalkan IH, Yesil Y, Ibis M. Serum Nitric Oxide Levels in Patients With Benign and Malignant Biliary Disease: A Prospective Single Center Study. Journal of Clinical Gastroenterology 2013;47:258-63. [DOI: 10.1097/mcg.0b013e318263ccd1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
99 La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, Russello D. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein. World J Gastroenterol 2012;18:4150-5. [PMID: 22919247 DOI: 10.3748/wjg.v18.i31.4150] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
100 Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008;9:149-158. [PMID: 18237849 DOI: 10.1016/s1470-2045(08)70027-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
101 Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2019;42:898-902. [DOI: 10.1097/coc.0000000000000620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]